Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.

Briefly, the predefined statistical criteria used to identify biomarkers of potential interest included: a fully adjusted, significant (false discovery rate of ≤0.05) prospective association with VTE in the tofacitinib treatment arm(s) or a nominally significant association in conjunction with a fully significant treatment effect (tofacitinib vs TNFi) on the change in biomarker levels in a direction matching the association with VTE risk.

also in 7,732 other papers